Physician profile
Brandi C Wright
NPI 1740627603
$5,718.29
in general payments reported to CMS, 2019-2025
40 companies · $701 in 2025
The $701 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $924 · 2022: $1,140 · 2023: $1,469 · 2024: $1,484 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,654.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,051.20 | 2021-2025 | |
| Novo Nordisk INC | $729.79 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $464.74 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $407.13 | 2022-2024 | |
| Lilly USA, LLC | $344.73 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $209.85 | 2021-2022 | |
| Pfizer INC. | $206.82 | 2023-2024 | |
| Glaxosmithkline, LLC. | $199.95 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $174.52 | 2022 | |
| Astellas Pharma US INC | $162.06 | 2023-2024 | Veozah, Myrbetriq |
| Inspire Medical Systems, INC. | $145.50 | 2024-2025 | Inspire |
| Biosense Webster, INC. | $138.17 | 2023 | Octaray Mapping Catheter |
| Stryker Corporation | $117.36 | 2023-2024 | Infinity Adaptis, Mako |
| Dexcom, INC. | $115.72 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $110.77 | 2021-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $107.93 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.51 | 2022-2024 | Xifaxan |
| Mimedx Group, INC. | $91.24 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $82.51 | 2021 | |
| Esperion Therapeutics, INC. | $78.54 | 2021-2022 | |
| Abbott Laboratories | $70.29 | 2022-2023 | Freestyle Libre 3 |
| Corium, LLC | $65.99 | 2022-2024 | Azstarys |
| Exact Sciences Corporation | $62.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $54.15 | 2023-2025 | Repatha, Otezla, Repatha |
| Antares Pharma, INC. | $53.03 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Takeda Pharmaceuticals U.S.A., INC. | $52.16 | 2021 | |
| Sumitomo Pharma America, INC. | $39.15 | 2023 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $33.90 | 2025 | Austedo Xr |
| Clarus Therapeutics INC. | $32.15 | 2021 | |
| Merck Sharp & Dohme LLC | $31.71 | 2021 | |
| Idorsia Pharmaceuticals US INC | $26.88 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $25.37 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $22.21 | 2023 | Seglentis |
| Abiomed | $20.68 | 2025 | |
| Tolmar, INC. | $17.91 | 2024 | |
| Corcept Therapeutics | $16.69 | 2025 | Korlym |
| Currax Pharmaceuticals LLC | $15.30 | 2023 | Contrave |
| Ironwood Pharmaceuticals, INC | $14.89 | 2023 | Linzess |
| Genentech USA, INC. | $14.73 | 2022 | |
| Acerus Pharmaceuticals Corporation | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.